#Tositumomab is a monoclonal antibody derived from immortalized mouse cells. It is a IgG2a anti-CD20 antibody and is covalently bound to 131I. 131I emits both beta and gamma radiation and decays with a half-life of 8 days..
#(S1 (S (NP (NNP Tositumomab)) (VP (AUX is) (NP (NP (DT a) (JJ monoclonal) (NN antibody)) (VP (VBN derived) (PP (IN from) (NP (NP (JJ immortalized) (NN mouse) (NN cells.)) (SBAR (S (NP (PRP It)) (VP (VP (AUX is) (NP (DT a) (NNP IgG2a) (CD anti-CD20) (NN antibody))) (CC and) (VP (AUX is) (RB covalently) (VP (VBN bound) (S (VP (TO to) (VP (VB 131I.) (NP (NP (JJ 131I) (NNS emits)) (CC both) (NP (NP (NN beta) (CC and) (NN gamma) (NN radiation) (CC and) (NNS decays)) (PP (IN with) (NP (NP (DT a) (NN half-life)) (PP (IN of) (NP (CD 8) (NNS days)))))))))))))))))) (. .))) (. .)))
#Rule:Nouns
r1TositumomabOrganizationAnnotation
r1antibodyNN
r1mouseNN
r1cellsNN
r1IgG2aLocationAnnotation
r1antibodyNN
r1emitsNNS
r1betaNN
r1gammaNN
r1radiationNN
r1decaysNNS
r1half-lifeNN
r1daysNNS

#Rule:Verbs
r2derivedVBN
r2boundVBN
r2131iVB

#Rule:Adjs
r4monoclonalJJ
r4immortalizedJJ
r4131IJJ

#Rule:Adj-Noun
r5monoclonalJJantibodyNN
r5immortalizedJJcellsNN
r5anti-CD20CDantibodyNN
r5131IJJemitsNNS
r58CDdaysNNS

#Rule:N-HeadNoun
r8mouseNNcellsNN
r8gammaNNradiationNN

#Rule:HeadNoun-V
r11TositumomabOrganizationAnnotationisAUX
r11itPRPisAUX

#Rule:NP(NP(z) SBAR(S(NP(x)VP(y))))
r19boundVBNcellsNN

#Rule:V-HeadNoun
r21isAUXantibodyNN
r21isAUXantibodyNN
r21131iVBemitsNNS

#Rule:V-HeadNoun(passive)
r23boundVBNitPRP

#Rule:V-HeadNoun(passive)
r24derivedVBNantibodyNN

#Rule:PPinNP
r26radiationNNwithINhalf-lifeNN
r26half-lifeNNofINdaysNNS

#Rule:PPinVP
r32derivedVBNfromINcellsNN

#Rule:V-V
r44boundVBN131iVB

#Rule:V-ADV
r46isAUXcovalentlyRB

#Rule:IS-RULE
r47antibodyNNTositumomabOrganizationAnnotation

#Clinical trials have established the efficacy of tositumomab in patients with relapsed or chemotherapy/rituxan refractory follicular lymphoma..
#(S1 (S (NP (JJ Clinical) (NNS trials)) (VP (AUX have) (VP (VBN established) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NP (NN tositumomab)) (PP (IN in) (NP (NNS patients))) (PP (IN with) (NP (ADJP (JJ relapsed) (CC or) (JJ chemotherapy/rituxan)) (JJ refractory) (JJ follicular) (NN lymphoma))) (. .)))))) (. .)))
#Rule:Nouns
r1trialsNNS
r1efficacyNN
r1tositumomabOrganizationAnnotation
r1patientsNNS
r1lymphoma..OrganizationAnnotation

#Rule:Verbs
r2establishedVBN

#Rule:Adjs
r4ClinicalOrganizationAnnotation
r4relapsedJJ
r4chemotherapy/rituxanJJ
r4refractoryJJ
r4follicularJJ

#Rule:Adj-Noun
r5ClinicalOrganizationAnnotationtrialsNNS
r5relapsedJJlymphoma..OrganizationAnnotation
r5chemotherapy/rituxanJJlymphoma..OrganizationAnnotation
r5refractoryJJlymphoma..OrganizationAnnotation
r5follicularJJlymphoma..OrganizationAnnotation

#Rule:HeadNoun-V
r12trialsNNSestablishedVBN

#Rule:V-HeadNoun
r21establishedVBNefficacyNN

#Rule:PPinNP
r26efficacyNNofINtositumomabOrganizationAnnotation
r26tositumomabOrganizationAnnotationinINpatientsNNS
r26tositumomabOrganizationAnnotationwithINlymphoma..OrganizationAnnotation

#It is manufactured by Corixa. It sells in the U.S. under the trade name Bexxar..
#(S1 (S (S (NP (PRP It)) (VP (AUX is) (VP (VBN manufactured) (PP (IN by) (NP (NNP Corixa.)))))) (NP (PRP It)) (VP (VBZ sells) (PP (IN in) (NP (DT the) (NNP U.S.))) (PP (IN under) (NP (NP (DT the) (NN trade) (NN name)) (NP (NNP Bexxar) (. .))))) (. .)))
#Rule:Nouns
r1CorixaLocationAnnotation
r1the U.S.LocationAnnotation
r1tradeNN
r1nameNN
r1BexxarOrganizationAnnotation

#Rule:Verbs
r2manufacturedVBN
r2sellsVBZ

#Rule:N-HeadNoun
r8tradeNNnameNN

#Rule:HeadNoun-V
r11itPRPsellsVBZ

#Rule:V-By-Agent
r13CorixaLocationAnnotationmanufacturedVBN

#Rule:V-HeadNoun(passive)
r23manufacturedVBNitPRP

#Rule:PPinVP
r30sellsVBZinINthe U.S.LocationAnnotation
r30sellsVBZunderINnameNN
r30sellsVBZunderINBexxarOrganizationAnnotation

#Ibritumomab tiuxetan, also sold under the trade name Zevalin??, is a monoclonal antibody radioimmunotherapy treatment for some forms of B cell non-Hodgkin s lymphoma, a myeloproliferative disorder of the lymphatic system. The drug uses the monoclonal mouse IgG1 antibody ibritumomab in conjunction with the chelator tiuxetan, to which a radioactive isotope (either yttrium-90 or indium-111) is added..
#(S1 (S (NP (NP (JJ Ibritumomab) (NN tiuxetan)) (, ,) (VP (ADVP (RB also)) (VBN sold) (PP (IN under) (NP (NP (DT the) (NN trade) (NN name)) (NP (NNP Zevalin) (CD ??))))) (, ,)) (VP (AUX is) (SBAR (S (NP (NP (NP (DT a) (JJ monoclonal) (NN antibody)) (JJ radioimmunotherapy) (NN treatment)) (PP (IN for) (NP (NP (DT some) (NNS forms)) (PP (IN of) (NP (NNP B) (NN cell) (NN non-Hodgkin)))))) (VP (VBZ s) (NP (NP (NN lymphoma)) (, ,) (NP (NP (DT a) (JJ myeloproliferative) (NN disorder)) (PP (IN of) (NP (NP (DT the) (JJ lymphatic) (NNS system.)) (SBAR (S (NP (DT The) (NN drug)) (VP (VBZ uses) (NP (DT the) (JJ monoclonal) (NN mouse) (NNP IgG1) (NN antibody) (NN ibritumomab)) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (DT the) (NN chelator) (NN tiuxetan)) (, ,) (SBAR (WHPP (TO to) (WHNP (WDT which))) (S (NP (NP (DT a) (JJ radioactive) (NN isotope)) (PRN (-LRB- -LRB-) (CC either) (NP (CD yttrium-90) (CC or) (CD indium-111)) (-RRB- -RRB-))) (VP (AUX is) (VP (VBN added))))))))))))))) (. .)))))) (. .)))
#Rule:Nouns
r1Ibritumomab tiuxetanPersonAnnotation
r1tradeNN
r1nameNN
r1ZevalinPersonAnnotation
r1antibodyNN
r1treatmentNN
r1formsNNS
r1BNNP
r1cellNN
r1non-HodgkinNN
r1lymphomaLocationAnnotation
r1disorderNN
r1systemNNS
r1drugNN
r1monoclonal mouse IgG1 antibody ibritumomabOrganizationAnnotation
r1conjunctionNN
r1chelatorNN
r1tiuxetanPersonAnnotation
r1isotopeNN

#Rule:Verbs
r2soldVBN
r2sVBZ
r2usesVBZ
r2addedVBN

#Rule:Adjs
r4monoclonalJJ
r4radioimmunotherapyJJ
r4myeloproliferativeJJ
r4lymphaticJJ
r4radioactiveJJ

#Rule:Adj-Noun
r5??CDZevalinPersonAnnotation
r5radioimmunotherapyJJtreatmentNN
r5monoclonalJJantibodyNN
r5myeloproliferativeJJdisorderNN
r5lymphaticJJsystemNNS
r5radioactiveJJisotopeNN
r5indium-111CDyttrium-90CD

#Rule:N-HeadNoun
r8tradeNNnameNN
r8cellNNnon-HodgkinNN
r8BNNPnon-HodgkinNN
r8chelatorNNtiuxetanPersonAnnotation

#Rule:N-ApposN
r10lymphomaLocationAnnotationdisorderNN

#Rule:HeadNoun-V
r11Ibritumomab tiuxetanPersonAnnotationisAUX
r11treatmentNNsVBZ
r11antibodyNNsVBZ
r11drugNNusesVBZ

#Rule:V-HeadNoun
r21sVBZlymphomaLocationAnnotation
r21usesVBZmonoclonal mouse IgG1 antibody ibritumomabOrganizationAnnotation

#Rule:V-HeadNoun(passive)
r23addedVBNisotopeNN

#Rule:V-HeadNoun(passive)
r24soldVBNIbritumomab tiuxetanPersonAnnotation

#Rule:PPinNP
r26treatmentNNforINformsNNS
r26formsNNSofINnon-HodgkinNN
r26disorderNNofINsystemNNS
r26conjunctionNNwithINtiuxetanPersonAnnotation

#Rule:PPinVP
r30usesVBZinINconjunctionNN

#Rule:PPinVP
r32soldVBNunderINnameNN
r32soldVBNunderINZevalinPersonAnnotation

#Rule:V-ADV
r46soldVBNalsoRB

#Consult your doctor..
#(S1 (S (VP (VB Consult) (NP (PRP$ your) (NN doctor)) (. .)) (. .)))
#Rule:Nouns
r1doctorNN

#Rule:Verbs
r2consultVB

#Rule:PRP-Noun
r6yourPRP$doctorNN

#Rule:V-HeadNoun
r21consultVBdoctorNN

#Please see the web pages for more details on Tositumomab (generic name) Bexxar (brand name) and Ibritumomab tiuxetan (generic name) Zevalin (brand name).
#(S1 (S (VP (VB Please) (VP (VB see) (NP (NP (DT the) (JJ web) (NNS pages)) (PP (IN for) (NP (NP (JJR more) (NNS details)) (PP (IN on) (NP (NP (NP (NNP Tositumomab) (PRN (-LRB- -LRB-) (NP (JJ generic) (NN name)) (-RRB- -RRB-)) (NNP Bexxar)) (PRN (-LRB- -LRB-) (NP (NN brand) (NN name)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Ibritumomab) (JJ tiuxetan) (-LRB- -LRB-) (JJ generic) (NN name) (-RRB- -RRB-) (NNP Zevalin)) (PRN (-LRB- -LRB-) (NP (NN brand) (NN name)) (-RRB- -RRB-)))))))))) (. .)))
#Rule:Nouns
r1pagesNNS
r1detailsNNS
r1TositumomabOrganizationAnnotation
r1nameNN
r1BexxarOrganizationAnnotation
r1brandNN
r1nameNN
r1Ibritumomab tiuxetanPersonAnnotation
r1nameNN
r1ZevalinPersonAnnotation
r1brandNN
r1nameNN

#Rule:Verbs
r2pleaseVB
r2seeVB

#Rule:Adjs
r4webJJ
r4moreJJR
r4genericJJ
r4genericJJ

#Rule:Adj-Noun
r5webJJpagesNNS
r5moreJJRdetailsNNS
r5genericJJnameNN
r5Ibritumomab tiuxetanPersonAnnotationZevalinPersonAnnotation
r5genericJJZevalinPersonAnnotation

#Rule:N-HeadNoun
r8brandNNnameNN
r8brandNNnameNN

#Rule:V-HeadNoun
r21seeVBpagesNNS

#Rule:PPinNP
r26pagesNNSforINdetailsNNS
r26detailsNNSonINBexxarOrganizationAnnotation
r26detailsNNSonINZevalinPersonAnnotation

@lemmas-left	IgG2a	treatment	lymphatic	immortalize	131I	page	derive	sold	form	immortalized	monoclonal	cell	system.	Tositumomab	monoclonal mouse IgG1 antibody ibritumomab	system	cells.	tositumomab	131i	8	lymphoma	cells	radiation	chelator	Clinical	B	use	beta	decays	patients	patient	gamma	sell	lymphoma..	trial	emits	refractory	b	pages	establish	established	web	i	days	s	relapse	brand	bound	Corixa	Bexxar	follicular	non-Hodgkin	myeloproliferative	Zevalin	doctor	??	please	more	derived	sells	trials	be	isotope	chemotherapy/rituxan	manufactured	efficacy	disorder	manufacture	relapsed	decay	cd	generic	half-life	mouse	tiuxetan	trade	antibody	radioimmunotherapy	conjunction	Ibritumomab tiuxetan	add	details	the U.S.	name	indium-111	hodgkin	forms	consult	drug	emit	is	it	added	your	see	anti-CD20	uses	radioactive	
@lemmas-right	Bexxar	treatment	non-Hodgkin	Zevalin	doctor	page	sells	covalently	trials	be	isotope	form	manufactured	efficacy	system.	Tositumomab	monoclonal mouse IgG1 antibody ibritumomab	system	cells.	disorder	tositumomab	manufacture	131i	yttrium-90	lymphoma	cells	half-life	radiation	tiuxetan	antibody	conjunction	use	Ibritumomab tiuxetan	patients	patient	details	sell	the U.S.	name	lymphoma..	hodgkin	trial	forms	emit	is	emits	it	pages	establish	established	i	days	s	uses	also	
@lemmas-center	of	with	for	under	on	from	in	